^
Association details:
| Biomarker: | NECTIN4 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | BT8009 (Microtubule inhibitor, Nectin-4-targeted peptide-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
Published date:
02/13/2023
Excerpt:
In the Part A 3+3 dose escalation portion of the study, BT8009 monotherapy was administered weekly (2.5, 5, 7.5 mg/m2) or every other week (7.5, 10 mg/m2) of a 28-day cycle, or on days 1 and 8 of a 21-day cycle (7.5 mg/m2)….Of 8 efficacy evaluable pts with UC treated with a RP2D of 5 mg/m2, there was 1 complete response, 3 partial responses (PR), and 3 stable diseases (SD), for an ORR of 50% and clinical benefit rate of 75% (CR+PR+SD≥16 wks).
DOI:
10.1200/JCO.2023.41.6_suppl.498
Trial ID:
